Home > News > IDT Shares Tips for Optimizing Target Capture
Industry Updates New Products Supplier News Upcoming Events business web

IDT Shares Tips for Optimizing Target Capture

Hits:1406   Date: 10/24/2014

Improving target capture for reliable data

CORALVILLE, IA – 23 October 2014 – In a recent DECODED Online article,  scientists at Geneseeq Technology, Inc., a cancer diagnostics company, demonstrate improved target capture methods for increasing reliability of next generation sequencing data, particularly important for clinical diagnostics. The scientists’ insights cover use of blocking oligos, optimizing hybridization conditions, and getting the most out of formalin-fixed and paraffin embedded (FFPE) samples.

IDT Shares Tips for Optimizing Target Capture

Geneseeq provides clinicians with guided treatment solutions for cancer, based on comprehensive, systematic analysis of patients’ genomic mutations. The company was an early adopter of IDT’s xGen® Lockdown® Probes and uses these with xGen® Blocking Oligos to capture specific regions of cancer patients’ DNA for sequencing. Identification of cancer-promoting genetic defects helps clinicians make informed decisions about which therapies are suitable for individual patients. The company gained valuable experience from close collaboration with IDT scientists during probe development and protocol optimization. The optimized protocol is available on the IDT website.

Full of helpful suggestions and compelling results, the article will be of particular benefit to researchers who are establishing their target capture protocols. The scientists also present the reasons behind their choice of target capture product and sequencing platform.

For more information, please visit www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.

About IDT
Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the world, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. IDT synthesizes and ships an average of 44,000 custom oligos per day to more than 82,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, California; Leuven, Belgium; and Singapore. For more information, visit
www.idtdna.com.

Integrated DNA Technologies
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)
productinfo@idtdna.com
www.idtdna.com